Effect of RhizomK on Testosterone Levels, the Anabolic Response to Exercise and Overall Quality of Life in Physically Active Healthy Males
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: RhizomK, Plcebo.
- Who it may be relevant to
- Registry conditions: Adult Healthy Volunteers. Basic parameters: 21 years — 40 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- India
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Randomized Double-blind Placebo Controlled Clinical Study to Evaluate the Impacts of RhizomK as Compared to Placebo on Testosterone Levels, the Anabolic Response to Exercise and Overall Quality of Life in Physically Active Healthy Males
Overview
Given that testosterone is a key modulator of muscle protein synthesis and overall anabolic response to resistance training, any natural intervention that boosts testosterone levels could logically contribute to improved exercise performance, lean muscle gain, and subjective vitality. 13 However, despite encouraging preclinical and ethnopharmacological data, clinical validation of Curculigo extract in human participants-especially in the context of exercise and lifestyle enhancement-is lacking. A novel extract of Curculigo orchioides (commercially known as RhizomK™) has been developed. This randomized, double-blind, placebo-controlled study seeks to bridge this crucial gap by evaluating the efficacy and safety of RhizomK™ supplementation in healthy, physically active males. The findings of this study have the potential to substantiate RhizomK™ as a scientifically supported dietary intervention for enhancing hormonal balance, physical performance, and well-being in men who are not candidates for pharmacological therapy but are seeking to optimize their health through lifestyle and supplementation.
Interventions
- Drug RhizomK
RhizomK 50 mg once daily - Other Plcebo
Placebo matching to RhizomK
Primary outcome measures
- Serum testosterone levels [Time frame: 4 weeks]
Secondary outcome measures (4)
- Serum cortisol levels [Time frame: 4 weeks]
- Quality of life using SF-36 (Short Form 36-Item Health Survey) [Time frame: 4 weeks]
- Exercise performance [Time frame: 4 weeks]
- Adverse effect [Time frame: 4 weeks]
Eligibility criteria
Inclusion criteria
- Male sex, aged 21 to 40 (inclusive)
- Currently engaged in, and has been engaged in resistance training
- (i.e., weightlifting), training three or more times per week for at least
- the prior 12 months.
- Healthy subject (no medical conditions that per the PI assessment).
- No significant past medical history
- No significant past surgical history that in the opinion of the PI
- would preclude study participation.
- Passes the screening with Physical Activity Readiness questionnaire (PAR-Q)
- Not currently or recently (within the prior eight-weeks) taken a
- dietary supplement that is purported to increase testosterone
- levels.
- Agrees to follow and adhere to the study directions.
- Agrees that their study visits will be scheduled at a similar time of the day
- to minimize and potential circadian rhythm impacts.
Exclusion criteria
- Takes any prescribed medication or over-the-counter medication which is known to affect testosterone levels.
- Positive medical history of heart disease/cardiovascular disease, high blood pressure (140/90 or greater mmHg), kidney disease, hepatic impairment or disease, or Type I or Type II diabetes or any other medical condition or diagnosis that the PI would deem exclusionary.
- Positive medical history of unstable thyroid disease, previously diagnosed major affective disorder, psychiatric disorder that required hospitalization in the prior year, immune disorder (i.e., HIV/AIDS), a history of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit.
- Positive medical history for any gastrointestinal disease or illness Positive history of gastrointestinal surgery that is known to alter or impact the digestion, absorption of nutrients and or fluids (i.e., gastric bypass).
- History of hospitalization or in-patient or out-patient treatment for alcohol dependence or drug addiction over the past one year.
- History of hospitalization or in-patient treatment for depression or any mental health related condition within the past one year.
- Allergic to any of the ingredients in the study product.
- Subject is unwilling to follow study directions.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Prevention
Study locations
India · 1 center
- All India Institute of Medical Sciences — Bhubaneswar
Publications
- Hackney AC. Hypogonadism in Exercising Males: Dysfunction or Adaptive-Regulatory Adjustment? Front Endocrinol (Lausanne). 2020 Jan 31;11:11. doi: 10.3389/fendo.2020.00011. eCollection 2020. PMID 32082255
- Osterberg EC, Bernie AM, Ramasamy R. Risks of testosterone replacement therapy in men. Indian J Urol. 2014 Jan;30(1):2-7. doi: 10.4103/0970-1591.124197. PMID 24497673
Identifiers
NCT: NCT07143474 · T/IM-NF/Pharm/25-26/29